PBH (PBH) SVP Jose Rosado receives 3,426 restricted stock units in grant

Rhea-AI Filing Summary

Prestige Consumer Healthcare senior vice president Jose Luis Rosado reported receiving 3,426 shares of common stock on January 6, 2026, at a price of $0 per share, bringing his direct holdings to 3,436 shares.

The award represents restricted stock units that are scheduled to fully vest on January 6, 2030, indicating a long-term, equity-based component to his compensation aligned with the company’s future performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosado Jose Luis

(Last) (First) (Middle)

660 WHITE PLAINS ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Prestige Consumer Healthcare Inc. [ PBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.01 per share	01/06/2026		A		3,426(1)	A	$0	3,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units vest on January 6, 2030.

Remarks:

SVP-Quality & Regulatory Affairs

	/s/ Jose L. Rosado by William P'Pool Attorney-in-Fact pursuant to Power of Attorney dated January 20, 2026 on file with the Commission	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PBH executive Jose Luis Rosado report?

Jose Luis Rosado reported acquiring 3,426 shares of Prestige Consumer Healthcare common stock at $0 per share. This equity award increased his directly held shares to 3,436, reflecting stock-based compensation rather than an open-market purchase.

When did the PBH insider transaction by Jose Luis Rosado occur?

The reported transaction occurred on January 6, 2026. On this date, Jose Luis Rosado received 3,426 shares of Prestige Consumer Healthcare common stock as part of an equity award, with no cash price paid per share in the transaction.

How many Prestige Consumer Healthcare shares does Rosado hold after this transaction?

After the award, Jose Luis Rosado beneficially owns 3,436 shares of Prestige Consumer Healthcare common stock directly. This figure reflects the updated total holdings reported following the January 6, 2026 stock-based compensation grant.

What type of equity award did PBH grant to Jose Luis Rosado?

The filing indicates an award of restricted stock units tied to Prestige Consumer Healthcare common stock. These units convert into shares over time, aligning executive compensation with long-term company performance rather than immediate cash payments.

When do Jose Luis Rosado’s restricted stock units in PBH vest?

The restricted stock units granted to Jose Luis Rosado are scheduled to vest on January 6, 2030. Vesting on this future date means he must remain eligible until then to fully realize the underlying shares.

Was cash paid for the PBH shares received by Jose Luis Rosado?

No cash was paid per share in this transaction; the filing reports a $0 price for the 3,426 shares. This indicates the shares were granted as compensation rather than bought on the open market.